Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)

NCT05288023 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

169707

Enrollment

OTHER

Sponsor class

Stopped AVENIR I demonstrated efficacy of azithromycin MDA targeted to children 1-59 over 1-11 months in July 2023, thus this trial was stopped before outcomes were collected so Niger could expand the program nationally to include children 1-59 months.

Conditions

Resistance Bacterial
Morality
Child Health
Implementation

Interventions

DRUG: Azithromycin for Oral Suspension

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]